Merz Receives CE Mark for Radiesse® (+) Lidocaine
Merz Pharma today announced that its dermal filler Radiesse Lidocaine, with integral 0.3% Lidocaine, has received the CE mark and will soon be available to physicians in Europe.
Radiesse Lidocaine provides an immediate lifting effect and stimulates the natural production of collagen, providing the lasting results that patients and physicians expect from Radiesse1-2 , as well as significant reduction in pain due to the addition of lidocaine within each syringe3 .
“For many years, Radiesse has been a cornerstone of Merz’s global aesthetics portfolio. We are excited to introduce Radiesse Lidocaine, a technology that delivers the trusted properties of Radiesse along with enhanced patient comfort,” stated Can Gumus, Vice President of Global Marketing Aesthetics for Merz Pharmaceuticals. “Merz’s research and development programs are strongly committed to meeting key unmet needs of physicians and patients around the world. The addition of Radiesse Lidocaine is an important step as we continue to build on the unique technology platform underlying Radiesse.”
Radiesse Lidocaine injectable implant is an opaque, dermal filler that contains a small quantity of local anesthetic (lidocaine). In Europe, Radiesse Lidocaine is indicated for plastic / reconstructive procedures, including deep dermal and subdermal soft tissue augmentation of the facial area and for restoration and correction of facial volume loss. The presence of lidocaine is intended to reduce patient pain and to enhance comfort during treatment.
“In my practice, treatment comfort is a concern for the majority of my patients, and Radiesse is the number one dermal filler that I use,” stated Dr. Jani van Loghem. “Now with Radiesse Lidocaine, I can fulfill the aesthetic desires of my patients with a safe, effective dermal filler that provides both immediate lift and the enhanced comfort that they are seeking.” A specialist in aesthetic medicine, Dr. Jani van Loghem is a medical biologist and a medical doctor by training. He works in his private practice in Amsterdam as managing director of Doctors Inc., providing the full spectrum of aesthetic treatments with a heavy focus on injectables.
As of April 2016, Merz has distributed more than six million syringes of Radiesse worldwide. Radiesse received the CE mark for aesthetic use in Europe in 2004, with U.S. FDA approval following in 2006. In that time, Radiesse has emerged as a leading non-invasive aesthetic treatment trusted by healthcare providers around the world.
In a clinical study3 , 101 patients received Radiesse on one side of the face and Radiesse Lidocaine on the other side of the face. Patients rated their pain on a scale of 0 to 10. On the scale, 0 was no pain and 10 was very severe pain. Immediately after injection, patients rated their pain about 6.7 on a scale of 0 to 10 for the side of the face injected with Radiesse compared to about 2.3 on the same scale for the side of the face treated with Radiesse Lidocaine. Sixty (60) minutes after treatment, patients rated their pain about 1.1 on a scale of 0 to 10 for the side of the face injected with Radiesse compared to about 0.3 on the same scale for the side of the face treated with Radiesse Lidocaine.
For more information about the full range of Merz Aesthetics products available in Europe, please click here.
For more information on Merz Pharma Group, please click here .
1 Sundaram H, Voigts B, Beer K, Meland M. Comparison of the rheological properties of viscosity and elasticity in two cate-gories of soft tissue fillers: calcium hydroxylapatite and hyaluronic acid. Dermatol Surg. 2010;36 (suppl 3):1859-1865.
2 Berlin AL, Hussain M, Goldberg DJ. Calcium hydroxylapatite filler for facial rejuvenation: a histologic and immunohisto-chemical analysis. Dermatol Surg. 2008;34 (suppl 1):S64-S67.
3 Schachter Science Brief: Pain Control using the Injectable Dermal Filler Radiesse (+) for the correction of Nasolabial folds. Daniel Schachter, Vince Bertucci, Nowell Solish. POSTER PRESENTATION at 13th Anti-Aging Medicine World Congress (2015), Monaco, Monte Carlo.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PIERRE-FABRE23.6.2018 13:02 | pressemeddelelse
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress
SERVIER23.6.2018 10:12 | pressemeddelelse
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho
SOFTOMOTIVE22.6.2018 17:15 | pressemeddelelse
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA
TX-ASCEND-PERFORMANCE22.6.2018 16:02 | pressemeddelelse
Ascend Performance Materials Announces Price Increase for Intermediate Materials
DELTICOM-AG/MOTO-TYRES.C22.6.2018 15:43 | pressemeddelelse
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk
BOEHRINGER-INGELHEIM22.6.2018 14:02 | pressemeddelelse
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum